Fulgent Genetics Inc (FLGT)
Return on total capital
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings before interest and tax (EBIT) (ttm) | US$ in thousands | -75,357 | -92,709 | -67,277 | -71,838 | -78,393 | -78,134 | -83,111 | -42,291 | 182,823 | 366,876 | 523,031 | 601,942 | 672,021 | 747,105 | 652,536 | 558,912 | 290,158 | 63,840 | 1,826 | -519 |
| Long-term debt | US$ in thousands | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Total stockholders’ equity | US$ in thousands | 1,133,230 | 1,138,440 | 1,132,550 | 1,129,940 | 1,136,100 | 1,258,700 | 1,259,760 | 1,268,920 | 1,269,880 | 1,281,400 | 1,304,760 | 1,312,960 | 1,165,880 | 1,036,780 | 920,725 | 801,566 | 569,387 | 186,955 | 87,043 | 81,372 |
| Return on total capital | -6.65% | -8.14% | -5.94% | -6.36% | -6.90% | -6.21% | -6.60% | -3.33% | 14.40% | 28.63% | 40.09% | 45.85% | 57.64% | 72.06% | 70.87% | 69.73% | 50.96% | 34.15% | 2.10% | -0.64% |
December 31, 2024 calculation
Return on total capital = EBIT (ttm) ÷ (Long-term debt + Total stockholders’ equity)
= $-75,357K ÷ ($—K + $1,133,230K)
= -6.65%
Based on the provided data, Fulgent Genetics Inc's return on total capital has shown fluctuating trends over the specified quarters. The company experienced a negative return on total capital of -0.64% as of March 31, 2020, indicating some inefficiency in capital deployment. However, there was a notable improvement in performance by June 30, 2020, with a return of 2.10%.
The most significant surge in return on total capital was observed on a year-over-year basis, reaching a peak of 72.06% as of September 30, 2021. This sharp increase suggests the company made efficient use of its total capital to generate profits during that period.
Subsequently, there was a slight decline in return on total capital by the end of the year, but it remained relatively high at 57.64% as of December 31, 2021. Nevertheless, the performance deteriorated in the following quarters, dropping to 6.36% by March 31, 2024 and further deteriorating to -6.65% as of December 31, 2024.
Overall, Fulgent Genetics Inc's return on total capital exhibited volatility over the analyzed timeframe, with periods of both strong performance and declines. It would be essential for the company to maintain a focus on efficient capital utilization to support sustainable growth and profitability in the future.
Peer comparison
Dec 31, 2024